Logo image
Sign in
Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial
Journal article   Peer reviewed

Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial

D. Chase, M. Sill, M. Chambers, K. Darcy, E. Han, J. Fruehauf, B. Monk, B. Buening, J. Sorosky and R. Burger
Gynecologic oncology, Vol.120, pp.S65-S66
03/01/2011

Metrics

4 Record Views

Details